Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases.

Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease.

The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease.

In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019.

Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.